Safety and Tolerability of More than Six Days of Tedizolid Treatment.
Por:
Mensa Vendrell M, Tasias Pitarch M, Salavert Lletí M, Calabuig Muñoz E, Morata Ruiz L, Castells Lao G, López Suñé E, Mensa Pueyo J, Oltra Sempere MR, Pedro-Botet Montoya ML, Isernia V, Reynaga Sosa EA, Moreno Nuñez L, Pasquau Liaño J, Sequera Arquelladas S, Yuste Ara JR and Soriano Viladomiu A
Publicada:
23 jun 2020
Ahead of Print:
23 jun 2020
Resumen:
Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce. The aim of the study was to assess the indications and to describe the long-term safety profile of tedizolid. A multicentric retrospective study of patients who received tedizolid for more than 6 days was conducted. Adverse events (AEs) were identified from patients' medical records and laboratory data. The World Health Organization causality categories were used to discern AEs that were probably associated with tedizolid. Eighty-one patients, treated with tedizolid 200 mg once daily for a median (interquartile range [IQR]) duration of 28 (14 to 59) days, were included; 36 (44.4%) had previously received linezolid. The most common reasons for selecting tedizolid were to avoid linezolid potential toxicities or interactions (53.1%) or due to previous linezolid-related toxicities (27.2%). The most common indications were off-label, including prosthetic joint infections, osteomyelitis, and respiratory infections (77.8%). Overall, 9/81 patients (11.1%) experienced a probably associated AE. Two patients (2.5%) developed gastrointestinal disorders, 1 (1.2%) developed anemia, and 6 developed thrombocytopenia (7.4%) after a median (IQR) duration of treatment of 26.5 (17 to 58.5) days. Four (5%) patients discontinued tedizolid due to AEs. Among 23 patients with chronic renal failure (CRF), the rate of myelotoxicity was 17.4%, and only 8.7% had to stop tedizolid; 20 out of 22 with previous linezolid-associated toxicity had no AE. Long-term tedizolid treatments had good tolerance with rates of gastrointestinal AE and hematological toxicity lower than those reported with linezolid, particularly in patients with CRF and in those with a history of linezolid-associated toxicity.
Filiaciones:
Mensa Vendrell M:
Pharmacy Department, Hospital Plató, Barcelona, Spain
Tasias Pitarch M:
Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Salavert Lletí M:
Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Calabuig Muñoz E:
Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Morata Ruiz L:
Department of Infectious Diseases, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
Castells Lao G:
Pharmacy Department, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
López Suñé E:
Pharmacy Department, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
Mensa Pueyo J:
Department of Infectious Diseases, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
Oltra Sempere MR:
Department of Infectious Diseases, Hospital Clínico Universitario de València, Valencia, Spain
:
Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain
Isernia V:
Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain
Reynaga Sosa EA:
Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain
Moreno Nuñez L:
Department of Infectious Diseases, Hospital Universitario Fundación Alcorcón, Madrid, Spain
Pasquau Liaño J:
Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain
Sequera Arquelladas S:
Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain
Yuste Ara JR:
Department of Infectious Diseases, Clínica Universidad de Navarra, Navarra, Spain
Green Published
|